ID   BHY
AC   CVCL_1086
DR   BTO; BTO:0004588
DR   CLO; CLO_0001975
DR   EFO; EFO_0006539
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473142
DR   BioSample; SAMN10987691
DR   CCLE; BHY_UPPER_AERODIGESTIVE_TRACT
DR   Cell_Model_Passport; SIDM00986
DR   ChEMBL-Cells; CHEMBL3308711
DR   ChEMBL-Targets; CHEMBL1075399
DR   Cosmic; 753535
DR   Cosmic; 2296290
DR   Cosmic-CLP; 753535
DR   DepMap; ACH-000548
DR   DSMZ; ACC-404
DR   GDSC; 753535
DR   GEO; GSM886882
DR   GEO; GSM887947
DR   GEO; GSM1669620
DR   IARC_TP53; 25036
DR   LiGeA; CCLE_194
DR   LINCS_LDP; LCL-1208
DR   NCBI_Iran; C622
DR   PharmacoDB; BHY_92_2019
DR   Progenetix; CVCL_1086
DR   Wikidata; Q54796512
RX   PubMed=8985100;
RX   PubMed=17390010;
RX   PubMed=17719389;
RX   PubMed=18423281;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=25275298;
RX   PubMed=25485619;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Population: Japanese.
CC   Doubling time: ~70 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Homozygous (CCLE).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr118Glnfs*5 (c.351delG) (p.G117fs); Zygosity=Homozygous (PubMed=17390010; CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met160Val (c.478A>G); ClinVar=VCV000444396; Zygosity=Unspecified (PubMed=17390010).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu369Pro (c.1106T>C); Zygosity=Unspecified (PubMed=17390010).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=1.12%; East Asian, North=81.47%; East Asian, South=16.1%; South Asian=0.22%; European, North=0%; European, South=1.09% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25275298; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 12,13
ST   D16S539: 12
ST   D18S51: 14
ST   D21S11: 29,31.2
ST   D3S1358: 17
ST   D5S818: 10
ST   D7S820: 11,12
ST   D8S1179: 11,14
ST   FGA: 24
ST   Penta D: 13,14
ST   Penta E: 14 (PubMed=25275298)
ST   Penta E: 14,20 (PubMed=25877200)
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C34447; Head and neck squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 28
//
RX   PubMed=8985100; DOI=10.1002/(SICI)1097-0215(19970106)70:1<120::AID-IJC18>3.0.CO;2-P;
RA   Kawamata H., Nakashiro K.-I., Uchida D., Harada K., Yoshida H.,
RA   Sato M.;
RT   "Possible contribution of active MMP2 to lymph-node metastasis and
RT   secreted cathepsin L to bone invasion of newly established human
RT   oral-squamous-cancer cell lines.";
RL   Int. J. Cancer 70:120-127(1997).
//
RX   PubMed=17390010; DOI=10.3892/ijo.30.5.1089;
RA   Kawamata H., Omotehara F., Nakashiro K., Uchida D., Shinagawa Y.,
RA   Tachibana M., Imai Y., Fujimori T.;
RT   "Oncogenic mutation of the p53 gene derived from head and neck cancer
RT   prevents cells from undergoing apoptosis after DNA damage.";
RL   Int. J. Oncol. 30:1089-1097(2007).
//
RX   PubMed=17719389; DOI=10.1016/j.joms.2006.11.034;
RA   Erdem N.F., Carlson E.R., Gerard D.A., Ichiki A.T.;
RT   "Characterization of 3 oral squamous cell carcinoma cell lines with
RT   different invasion and/or metastatic potentials.";
RL   J. Oral Maxillofac. Surg. 65:1725-1733(2007).
//
RX   PubMed=18423281; DOI=10.1016/j.joms.2007.12.036;
RA   Erdem N.F., Carlson E.R., Gerard D.A.;
RT   "Characterization of gene expression profiles of 3 different human
RT   oral squamous cell carcinoma cell lines with different invasion and
RT   metastatic capacities.";
RL   J. Oral Maxillofac. Surg. 66:918-927(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//